Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/15505

Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers


Vista previa

Ver/Abrir:
 Targeting_Pablo_IJP_2023.pdf
6,19 MB
Adobe PDF
Título : Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers
Autor : Pablo, E. de
O'Connell, Peter
Fernández García, Raquel
Marchand, S.
Chauzy, A.
Tewes, F.
Dea Ayuela, María Auxiliadora
Kumar, D.
Bolás Fernández, Francisco
Ballesteros, M. P.
Torrado Durán, Juan José
Healy, Anne Marie
Serrano López, Dolores Remedios
Materias: AerosolesAerosol therapyUso terapéuticoTherapeutic usePulmonesLungsEnfermedadDiseasesMicrobiología farmacéuticaPharmaceutical microbiology
Editorial : Elsevier
Citación : De Pablo, E., O'Connell, P., Fernández-García, R., Marchand, S., Chauzy, A., Tewes, F., Dea-Ayuela, M.A., Kumar, D., Bolás, F., Ballesteros, M.P., Torrado, J.J., Healy, A.M. & Serrano, D.R. (2023). Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers. International Journal of Pharmaceutics, vol. 635, art. 122788. DOI: https://doi.org/10.1016/j.ijpharm.2023.122788
Resumen : The incidence of fungal pulmonary infections is known to be on the increase, and yet there is an alarming gap in terms of marketed antifungal therapies that are available for pulmonary administration. Amphotericin B (AmB) is a highly efficient broad-spectrum antifungal only marketed as an intravenous formulation. Based on the lack of effective antifungal and antiparasitic pulmonary treatments, the aim of this study was to develop a carbohydrate-based AmB dry powder inhaler (DPI) formulation, prepared by spray drying. Amorphous AmB microparticles were developed by combining 39.7 % AmB with 39.7 % γ-cyclodextrin, 8.1 % mannose and 12.5 % leucine. An increase in the mannose concentration from 8.1 to 29.8 %, led to partial drug crystallisation. Both formulations showed good in vitro lung deposition characteristics (80 % FPF < 5 µm and MMAD < 3 µm) at different air flow rates (60 and 30 L/min) when used with a DPI, but also during nebulisation upon reconstitution in water.
URI : http://hdl.handle.net/10637/15505
Derechos: http://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
Open Access
ISSN : 0378-5173
Fecha de publicación : 25-mar-2023
Centro : Universidad Cardenal Herrera-CEU
Aparece en las colecciones: Dpto. Farmacia





Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.